William Blair Reiterates Buy Rating for Spark Therapeutics (ONCE)

William Blair reaffirmed their buy rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a report released on Monday.

Several other analysts have also commented on ONCE. Zacks Investment Research lowered Spark Therapeutics from a hold rating to a sell rating in a research note on Thursday, November 8th. BMO Capital Markets lowered Spark Therapeutics from an outperform rating to a market perform rating and set a $60.00 price target on the stock. in a research note on Tuesday, August 7th. Leerink Swann reaffirmed a market perform rating and issued a $55.00 price target (down previously from $74.00) on shares of Spark Therapeutics in a research note on Tuesday, August 7th. Stifel Nicolaus decreased their price target on Spark Therapeutics from $76.00 to $68.00 and set a buy rating on the stock in a research note on Wednesday, August 8th. Finally, Royal Bank of Canada decreased their price target on Spark Therapeutics to $64.00 and set a sector perform rating on the stock in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the company’s stock. Spark Therapeutics currently has a consensus rating of Hold and an average price target of $65.95.

Shares of NASDAQ:ONCE opened at $39.55 on Monday. Spark Therapeutics has a 1-year low of $35.63 and a 1-year high of $96.59. The company has a market cap of $1.48 billion, a PE ratio of -5.18 and a beta of 2.25. The company has a current ratio of 10.71, a quick ratio of 10.36 and a debt-to-equity ratio of 0.09.



Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.04) by ($0.22). The company had revenue of $10.70 million during the quarter, compared to analyst estimates of $27.44 million. Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. Spark Therapeutics’s quarterly revenue was up 463.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.90) EPS. Research analysts expect that Spark Therapeutics will post -1.45 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of ONCE. Amalgamated Bank boosted its position in Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 1,100 shares during the last quarter. Aperio Group LLC boosted its position in Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 1,056 shares during the last quarter. Alps Advisors Inc. boosted its position in Spark Therapeutics by 8.2% during the second quarter. Alps Advisors Inc. now owns 53,708 shares of the biotechnology company’s stock valued at $4,445,000 after purchasing an additional 4,076 shares during the last quarter. State of Wisconsin Investment Board boosted its position in Spark Therapeutics by 21.9% during the second quarter. State of Wisconsin Investment Board now owns 32,300 shares of the biotechnology company’s stock valued at $2,673,000 after purchasing an additional 5,800 shares during the last quarter. Finally, C WorldWide Group Holding A S boosted its position in Spark Therapeutics by 23.5% during the second quarter. C WorldWide Group Holding A S now owns 51,596 shares of the biotechnology company’s stock valued at $4,270,000 after purchasing an additional 9,822 shares during the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: Fundamental Analysis and Individual Investors

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply